

Disease Knowledge Transfer across Neurodegenerative Diseases

Răzvan Marinescu^{1,2}, Marco Lorenzi³, Stefano Blumberg¹, Alexandra Young¹, Pere Morell¹, Neil Oxtoby¹, Arman Eshaghi^{1,4}, Keir Young⁵, Sebastian Crutch⁵, Polina Golland², Daniel Alexander¹

¹Centre for Medical Image Computing, UCL, UK

³University of Côte d'Azur, Inria Sophia Antipolis, France

⁵Dementia Research Centre, UCL, UK

²Computer Science and Artificial Intelligence Laboratory, MIT, USA

⁴Queen Square MS Centre, UCL Institute of Neurology, UK




Aim Infer progression of non-MRI biomarkers in rare neurodegenerative diseases (NDs) by leveraging larger datasets of common NDs.

Why Posterior Cortical Atrophy (PCA): progression of non-MRI biomarkers not known → Identify outcome measures and suitable subjects for PCA clinical trials

Method

1. Each disease characterised by region-specific dysfunction profile
2. Dysfunction score modelled using region-specific biomarkers




Challenges


- | | |
|----------------------------|-------------------------|
| Typical Neurodeg. Diseases | Rare Neurodeg. Diseases |
| • Large datasets ✓ | • Small datasets ✗ |
| • Multimodal imaging ✓ | • MRI only ✗ |
| • Longitudinal ✓ | • Cross-sectional ✗ |

Results

In synthetic experiment, the estimated parameters are close to the true parameters



Inferred multimodal trajectories for Posterior Cortical Atrophy are plausible, suggesting late-stage parietal and occipital damage.



Inference: Loopy belief propagation

Initialise $\theta^{(0)}, \lambda^{(0)}, \beta^{(0)}$

while θ, λ, β not converged **do**

```

; // Estimate biomarker trajectories (disease agnostic)
 $\theta_k^{(u)} = \arg \min_{\theta_k} \sum_{(i,j) \in \Omega_k} \left[ y_{ijk} - g \left( f(\beta_i^{(u-1)} + m_{ij}; \lambda_{d_i}^{\psi(k),(u-1)}); \theta_k \right) \right]^2$ 
; // Estimate dysfunction trajectories (disease specific)
 $\lambda_d^{l,(u)} = \arg \min_{\lambda_d^l} \sum_{(i,j,k) \in \Omega_{dl}} \left[ y_{ijk} - g \left( f(\beta_i^{(u-1)} + m_{ij}; \lambda_d^l); \theta_k^{(u)} \right) \right]^2$ 
; // Estimate subject-specific time shifts
 $\beta_i^{(u)} = \arg \min_{\beta_i} \sum_{(j,k) \in \Omega_i} \left[ y_{ijk} - g \left( f(\beta_i + m_{ij}; \lambda_{d_i}^{\psi(k),(u)}); \theta_k^{(u)} \right) \right]^2$ 

```

Demographics

- Dementia Research Center cohort: 76 PCA, 67 tAD, 87 age-matched controls for training, 10 PCA with DTI for validation
- TADPOLE Challenge dataset split into three subgroups with different progressions: 21 hippocampal, 35 cortical, 27 subcortical.
- Synthetic dataset mimicking the DRC cohort: 50 subjects with "synthetic PCA", 100 subjects with "synthetic AD".

Weblinks

- Source code: <https://github.com/mrazvan22/dkt>
- Website: <https://people.csail.mit.edu/razvan/>

Our model has favourable performance compared to other models, on two different datasets

Model	Cingulate	Frontal	Hippocam.	Occipital	Parietal	Temporal
TADPOLE: Hippocampal subgroup to Cortical subgroup						
DKT (ours)	0.56 ± 0.23	0.35 ± 0.17	0.58 ± 0.14	-0.10 ± 0.29	0.71 ± 0.11	0.34 ± 0.26
Latent stage	0.44 ± 0.25	0.34 ± 0.21	0.34 ± 0.24*	-0.07 ± 0.22	0.64 ± 0.16	0.08 ± 0.24*
Multivariate	0.60 ± 0.18	0.11 ± 0.22*	0.12 ± 0.29*	-0.22 ± 0.22	-0.44 ± 0.14*	-0.32 ± 0.29*
Spline	-0.24 ± 0.25*	-0.06 ± 0.27*	0.58 ± 0.17	-0.16 ± 0.27	0.23 ± 0.25*	0.10 ± 0.25*
Linear	-0.24 ± 0.25*	0.20 ± 0.25*	0.58 ± 0.17	-0.16 ± 0.27	0.23 ± 0.25*	0.13 ± 0.23*
typical Alzheimer's to Posterior Cortical Atrophy						
DKT (ours)	0.77 ± 0.11	0.39 ± 0.26	0.75 ± 0.09	0.60 ± 0.14	0.55 ± 0.24	0.35 ± 0.22
Latent stage	0.80 ± 0.09	0.53 ± 0.17	0.80 ± 0.12	0.56 ± 0.18	0.50 ± 0.21	0.32 ± 0.24
Multivariate	0.73 ± 0.09	0.45 ± 0.22	0.71 ± 0.08	-0.28 ± 0.21*	0.53 ± 0.22	0.25 ± 0.23*
Spline	0.52 ± 0.20*	-0.03 ± 0.35*	0.66 ± 0.11*	0.09 ± 0.25*	0.53 ± 0.20	0.30 ± 0.21*
Linear	0.52 ± 0.20*	0.34 ± 0.27	0.66 ± 0.11*	0.64 ± 0.17	0.54 ± 0.22	0.30 ± 0.21*

Conclusion

- Developed a novel methodology and model for transfer learning across different diseases
- Inferred multimodal trajectories for Posterior Cortical Atrophy

Funders



